作者
Leonard Stern,Richard J. Johnson,Payam Shakouri,Amod S. Athavale,Karim Richard Masri,Brian D. LaMoreaux,Brad A. Marder,Sreedhar A. Mandayam
摘要
Background: Gout is associated with higher mortality risk,1 multiple comorbidities,1-3 and decreased quality of life.3 Impaired renal function increases gout risk,4 but gout prevalence and impact on advanced CKD patients have not been thoroughly described. This study reports health burden of gout in CKD patients under the care of nephrologists. Methods: Nephrologists provided chart data on random Stage 3-5 CKD patients. Criteria to identify gout in this study: gout listed as comorbidity, urate-lowering therapy (ULT) use, or visible tophi/gout flare noted. Uncontrolled gout (UCG) was defined as serum urate >6 mg/dL with visible tophi, ≥2 flares in past year, or ≥1 swollen/tender joint. Gout prevalence was examined and patients with and without gout were compared. Results: 111 physicians reported on 746 patients (55% male, 56.2±18.3 yrs, BMI: 31.4±10.9 kg/m2) with Stage 3-5 CKD (duration: 4.0±4.8 yrs, eGFR: 32.2±15.5 ml/min/1.73 m2). 173 (23%) met gout criteria, with highest frequency in Stage 3b and 4 (both 28%). Of gout patients, 13% had UCG, 29% had no formal gout diagnosis, and 38% were not using a ULT. Compared to those without gout, gout patients more often sought acute medical care (30% vs 7% in prior yr) and, at presentation, more often had urination changes (15% vs 7%) and shortness of breath (21% vs 14%; all p≤0.02). Gout patients had more diagnoses of CKD-mineral bone disorder, ischemic heart disease, CHF, peripheral vascular disease, and chronic pain. Compared to controlled gout patients, UCG patients more often had pulmonary hypertension, joint issues, chronic pain, febuxostat use, and colchicine use. Conclusions: 1 in 5 advanced CKD patients had gout, of which 13% had UCG. Gout highly impacts advanced CKD patients, with increased healthcare utilization and higher cardiovascular and bone/joint comorbidity. Patients with uncontrolled gout have an even higher health burden and more frequent colchicine use (26%), which has worse toxicity profile in CKD patients. Among CKD patients, gout is common, impactful, and requires careful screening and collaborative management. References 1. Choi HK, Curhan G. Circulation 2007;116:894-900 2. Kuo CF et al. Ann Rheum Dis 2016;75:210-7 3. Singh JA, Strand V. Ann Rheum Dis 2008;67:1310-6 4. Safiri S et al. Arthritis Rheumatol 2020;72:1916-27 Funding: Commercial Support - Horizon Therapeutics plc